

### Phase IB

<b>Agent</b>	<b>Starting Dose</b>	<b>Dose Adjustment Level -1</b>	<b>Dose Adjustment Level -2</b>
<b>Dasatinib</b>	70mg 100mg 150mg 200mg 250mg	50mg 70mg 100mg 150mg 190mg	20mg 50mg 70mg 100mg 120mg
<b>Cetuximab*</b>	250 mg/kg	200mg/kg	150mg/kg
<b>Oxaliplatin</b>	85 mg/m <sup>2</sup>	70 mg/m <sup>2</sup>	65 mg/m <sup>2</sup>
<b>Leucovorin</b>	400 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	Discontinue
<b>5-FU 46-hr infusion</b>	2.4 gm/m <sup>2</sup>	2.0 gm/m <sup>2</sup>	1.8 gm/m <sup>2</sup>

\*After first dose of 400mg/kg on cycle 1, day 1, subsequent doses are 250mg/kg.

### Phase II

<b>Agent</b>	<b>Starting Dose</b>	<b>Dose Adjustment Level -1</b>	<b>Dose Adjustment Level -2</b>
<b>Dasatinib</b>	100mg	70mg	50mg
<b>Cetuximab (if applicable)</b>	500 mg/kg	400mg/kg	250mg/kg
<b>Oxaliplatin</b>	85 mg/m <sup>2</sup>	70 mg/m <sup>2</sup>	65 mg/m <sup>2</sup>
<b>Leucovorin</b>	400 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	Discontinue
<b>5-FU 46-hr infusion</b>	2.4 gm/m <sup>2</sup>	2.0 gm/m <sup>2</sup>	1.8 gm/m <sup>2</sup>

**Supplemental Table 3.** Prespecified dose modifications for adverse events related to study drug in Phase IB and Phase II.